Hans J. Hammers
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment
Papers in
-
- Renal cell carcinoma treatment 94
- Oncology 41
- Cancer Immunotherapy and Biomarkers 30
- Pancreatic and Hepatic Oncology Research 9
- CAR-T cell therapy research 7
- Co-authors
- Роберто Пили (16 shared papers)Brian I. Rini (26 shared papers)David F. McDermott (21 shared papers)Elizabeth R. Plimack (18 shared papers)Saby George (15 shared papers)Robert John Motzer (18 shared papers)Michael Anthony Carducci (16 shared papers)Ian M. Waxman (5 shared papers)
- Journals
- Annals of Oncology (14 papers)The Oncologist (10 papers)Clinical Genitourinary Cancer (10 papers)Journal for ImmunoTherapy of Cancer (9 papers)Clinical Cancer Research (6 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Hans J. Hammers
138 papers receiving 20.4k citations
Hans J. Hammers's Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 9.2k
- Pulmonary and Respiratory Medicine 10.3k
- Cancer Research 3.3k
- Immunology 2.6k
- Molecular Biology 5.0k
Countries citing papers authored by Hans J. Hammers
This map shows the geographic impact of Hans J. Hammers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans J. Hammers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans J. Hammers more than expected).
Fields of papers citing papers by Hans J. Hammers
This network shows the impact of papers produced by Hans J. Hammers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans J. Hammers. The network helps show where Hans J. Hammers may publish in the future.
Co-authors
The 25 scholars most cited alongside Hans J. Hammers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 149 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 3 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
| 4 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial Hit paper breakdown → | 2014 | 928 |
| 5 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2016 | 778 |
| 6 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 643 |
| 7 | 2008 | 549 | |
| 8 | Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 547 |
| 9 | Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study Hit paper breakdown → | 2017 | 390 |
| 10 | Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab Hit paper breakdown → | 2015 | 382 |
| 11 | 2004 | 330 | |
| 12 | 2017 | 275 | |
| 13 | 2020 | 247 | |
| 14 | 2019 | 211 | |
| 15 | Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma Hit paper breakdown → | 2022 | 210 |
| 16 | 2008 | 205 | |
| 17 | 2017 | 205 | |
| 18 | 2019 | 204 | |
| 19 | 2017 | 193 | |
| 20 | 2011 | 190 |
About Hans J. Hammers
Hans J. Hammers is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Immunology, having authored 149 papers that have together received 20.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (94 papers), Cancer Immunotherapy and Biomarkers (30 papers), Renal and related cancers (18 papers), Cancer Genomics and Diagnostics (16 papers), Pancreatic and Hepatic Oncology Research (9 papers), Bladder and Urothelial Cancer Treatments (8 papers), CAR-T cell therapy research (7 papers) and Histone Deacetylase Inhibitors Research (7 papers). The work is most often cited by research in Oncology (9.2k citations), Pulmonary and Respiratory Medicine (10.3k citations), Cancer Research (3.3k citations), Immunology (2.6k citations) and Molecular Biology (5.0k citations). Hans J. Hammers has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Роберто Пили, Brian I. Rini, David F. McDermott, Elizabeth R. Plimack, Saby George, Robert John Motzer, Michael Anthony Carducci, Ian M. Waxman, Leigh Ellis and Julie Renee Brahmer. Their work appears in journals such as Annals of Oncology, The Oncologist, Clinical Genitourinary Cancer, Journal for ImmunoTherapy of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.